Qatar Ministry of Public Health issued Emergency Use Authorization for COVID-19 Vaccine Moderna
On Feb. 11, 2021, Moderna announced that the Qatar Ministry of Public Health had issued an emergency use…
US Government purchased additional 100 million doses of Moderna’s COVID-19 Vaccine
On Feb. 11, 2021, Moderna announced that the U.S. government had purchased an additional 100 million doses of…
Oregon mink farm cleared from SARS-CoV-2; farm quarantine lifted
On Feb. 11, 2021, the Oregon Department of Agriculture (ODA) lifted the quarantine on the Oregon mink farm…
NIH’s TOPMed program published data on over 53,000 diverse genomes
On Feb. 10, 2021, researchers supported by the National Heart, Lung, and Blood Institute announced the publication of…
USDA confirmed COVID-19 in a cougar and tiger at a wild animal exhibitor in Texas
On Feb. 10, 2021, the United States Department of Agriculture (USDA) National Veterinary Services Laboratories announced confirmation of…
Notch Therapeutics closed $85 million financing to develop pipeline of renewable stem cell-derived cancer immunotherapies
On Feb. 10, 2021, Notch Therapeutics closed $85 Million Series A financing to develop pipeline of renewable stem…
Moderna announced COVID-19 vaccine supply agreements with governments of Taiwan and Colombia
On Feb. 9, 2021, Moderna announced two supply agreements for the COVID-19 Vaccine Moderna: one with the government…
Resurgence of Ebola reported in North Kivu in the Democratic Republic of the Congo
On Feb. 7, 2021, The Ministry of Health of the Democratic Republic of the Congo (DRC) announced that…
FDA approved new treatment for adults with relapsed or refractory large-B-Cell lymphoma
On Feb. 5, 2021, the FDA approved Breyanzi (lisocabtagene maraleucel), a cell-based gene therapy to treat adult patients…
Merck Statement on Ivermectin use During the COVID-19 Pandemic
On Feb. 4, 2021, Merck affirmed its position regarding use of ivermectin during the COVID-19 pandemic, and do…
T2 Biosystems T2SARS-CoV-2 panel proved capable of detecting the Brazil P1 variant of SARS-CoV-2 virus
On Feb. 4, 2021, T2 Biosystems announced that its T2SARS-CoV-2 Panel – a molecular diagnostic test that detects…
Corvus Pharmaceuticals initiated phase 3 clinical trial of CPI-006 for patients with COVID-19
On Feb. 4, 2021, Corvus Pharmaceuticals announced that it had initiated a Phase 3 clinical trial of CPI-006…
Novavax announced start of rolling review by multiple regulatory authorities for COVID-19 vaccine authorization
On Feb. 4, 2021, Novavax announced the start of the rolling review process for authorization of NVX-CoV2373, its…
AXIM Biotechnologies began clinical trials of ImmunoPass rapid diagnostic test with vaccine recipients
On Feb. 3, 2021, AXIM Biotechnologies announced initiation of clinical trials for ImmunoPass, the Companyﾒs rapid point-of-care test…
Quidel opens new manufacturing facility to mass produce QuickVue Rapid Antigen Tests for COVID-19
On Feb. 3, 2021, Quidel announced the opening of a new manufacturing facility in Carlsbad, CA that was…
First-in-human clinical trial confirmed novel HIV vaccine approach
On Feb. 3, 2021, IAVI and Scripps Research announced a phase 1 clinical trial testing a novel vaccine…
Moderna announced amendment to supply agreement with Switzerland for additional 6 million doses of COVID-19 vaccine
On Feb. 3, 2021, Moderna announced the Swiss Federal Government had increased its confirmed order commitment from 7.5…
Singapore Health Sciences Authority approved interim authorization of COVID-19 Vaccine Moderna
On Feb. 3, 2021, Moderna announced that the Singapore Health Sciences Authority (HSA) had approved the interim authorization…
Novavax and Government of Switzerland announced agreement in principle to supply COVID-19 vaccine
On Feb. 3, 2021, Novavax announced that the company had executed a binding Heads of Terms agreement with…
NIH study of Intranasal influenza vaccine spurred strong immune response in Phase 1 study
On Feb. 3, 2021, an experimental single-dose, intranasal influenza vaccine, was safe and produced a durable immune response…
NeuroRx initiated phase 2/3 study of inhaled ZYESAMI for severe COVID-19 with UCI Health
On Feb. 3, 2021, RELIEF THERAPEUTICS affirmed that its collaboration partner NeuroRx had initiated a phase 2/3 clinical…
Mateon announced completion of ARTI-19 and publication of positive interim data
On Feb. 2, 2021, Mateon Therapeutics announced that its ARTI-19 trial, evaluating ARTIVeda / PulmoHeal against COVID-19 in…
Novavax announced MOU to produce COVID-19 vaccine made in Canada
On Feb. 2, 2021, Novavax announced a memorandum of understanding (MOU) with the Canadian government to produce NVX-CoV2373,…
Sorrento announced the fourth patient was released from hospital following third infusion of stem cells
On Jan. 31, 2021, Sorrento Therapeutics announced additional positive results from its Phase 1b study of human allogeneic…
COVID-19 | Diagnostics | Disease | Life Science News | NIH | Women's Health
Severe COVID-19 in pregnancy associated with preterm birth, other complications
On Jan. 28, 2021, National Institutes of Health (NIH) researchers reported that pregnant women who experienced severe symptoms…
Researchers used patients’ cells to test gene therapy for rare eye disease
On Jan. 28, 2021, scientists at the National Eye Institute (NEI) have developed a promising gene therapy strategy…
New COVID-19 variants fueling Africa’s second wave
On Jan. 28, 2021, The WHO announced that COVID-19 cases and deaths were surging in Africa as more…
Mammoth Biosciences and Agilent partnered on high-throughput CRISPR-based SARS-CoV-2 diagnostic test
On Jan 28, 2021, Mammoth Biosciences announced a co-marketing agreement with Agilent Technologies to support the anticipated launch…
Precipio launched COVID-19 antibody testing at point-of-care
On Jan. 28, 2021, Precipio announced that following receipt of an Emergency Use Authorization from the U.S. Food…
Novavax COVID-19 vaccine demonstrated 89.3% efficacy in UK phase 3 trial
On Jan. 28, 2021, Novavax announced that NVX-CoV2373, its protein-based COVID-19 vaccine candidate, had met the primary endpoint,…